Last mentioned: Mar 18, 2026
Inovio PDUFA Date
Target date for FDA decision on INO-3107 biologics license application.
LivePerson Syntrix Launch
Full commercial availability of Syntrix platform announced for enterprise banking and tech.
Bakkt Capital Raise
Registered direct offering raises $48.1 million to bolster cash reserves.
Bakkt Debt Extinguished
Company completes the elimination of all long-term debt and simplifies cap table.
LivePerson exceeded Q4 2025 expectations with $59.3 million in revenue and $10.8 million in Adjusted EBITDA, driven by the commercial launch of its Syntrix platform and aggressive cost discipline. While total revenue continues a sequential decline due to legacy churn, the company is betting on a unified AI architecture and high-value enterprise expansions to return to growth by late 2026.
Bakkt reported a revenue decline to $2.3 billion following a restructured Webull agreement but achieved a debt-free balance sheet and expanded into stablecoin settlement. Meanwhile, LivePerson saw 20% of customer interactions driven by generative AI as it launched its Syntrix platform, signaling a broader shift toward high-utility infrastructure.
LivePerson, Inovio, and Bakkt reported Q4 2025 results highlighting strategic transitions toward AI integration, regulatory milestones, and balance sheet restructuring. While LivePerson capitalizes on generative AI adoption and Inovio nears a critical FDA PDUFA date, Bakkt has streamlined its capital structure to focus on institutional crypto services.